N/A N=1,463 Virtual Gout Clinic
Gout
Primary: sUA < 6.0 mg/dl at 1 Year — 117; 204 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=43 The Diet Gout Trial
Gout · Hyperuricemia
Primary: Uric Acid Level — 8.23; 8.03 mg/dL
Phase 4 N=74 An Assessment of Chronic Synovial-Based Inflammation and Its Role With Serum Urate Levels.
Gout
Primary: Number and Percentage of Participants With Evidence of Chronic Ongoing Synovial-Based Inflammatory Disease at Baseline. — 63 Participants — p=0.34
Phase 2 N=37 Pegylated Recombinant Mammalian Uricase (PEG-uricase) as Treatment for Refractory Gout
Gout
Primary: Reduction in Plasma Uric Acid to Less Than 6 mg/dL. — 17 Participants
Phase 2 N=60 Traditional Chinese Medicine in the Treatment of Patients With Hyperuricemia.
Hyperuricemia
Primary: Serum Uric Acid<6 mg/dL at Week 4 — 0; 1; 1 Participants
Phase 4 N=24 Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome
Gout
Primary: BMI — 33.4 kg/m^2
Phase 3 N=225 Safety and Efficacy Study of PEG-uricase in the Treatment of Hyperuricemic Patients With Symptomatic Gout
Gout
Primary: Plasma Uric Acid (PUA) Responder — 36; 29; 0 Participants — p=<0.001
N/A N=60 Gout Self-Monitoring Aiming to Reach Target
Gout
Primary: Percentage of Participants Achieving Target Urate Levels (24 Weeks) — 29; 3 Participants
Phase 2 N=314 Effect of Febuxostat on Joint Damage in Hyperuricemic Subjects With Early Gout
Joint Damage
Primary: Mean Change From Baseline to Month 24 in the Modified Sharp/Van Der Heijde Erosion Score of the Single Affected Joint — 0.16; 0.11; 0.01; 0.01 score on a scale — p=0.472
Phase 2 N=143 A Study to Assess Efficay and Safety of LC350189 Different Doses in Gout Patients With Hyperuricemia
Gout · Hyperuricemia
Primary: Percentage of Participants With sUA (Serum Uric Acid) < 5.0 mg/dL at Day 84 — 47.1; 44.7; 62.2; 2.9 Percentage of participants
Phase 3 N=142 Uric Acid and Hypertension in African Americans
Cardiovascular Diseases · Heart Diseases · Hypertension
Primary: Change in Diastolic Blood Pressure by Cuff 8-10 Weeks Minus Baseline — 3.44; -0.83 mm Hg — p=0.059
Phase 4 N=196 Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout
Gout
Primary: Pulse Wave Velocity — 9.0; 9.05 m/s — p=0.5298
Phase 4 N=940 CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat
Gout · Chronic Kidney Diseases
Primary: Percentage of Participants Experiencing ≥ 1 Gout Flare During Phase 3 — 135; 165 Participants — p=<0.001
Phase 3 N=2,269 Efficacy and Safety of Oral Febuxostat in Participants With Gout
Gout
Primary: Percentage of Subjects Whose Serum Urate Level is <6.0 Milligrams Per Deciliter (mg/dL) at the Final Visit. — 45.2; 67.1; 42.1 percentage of subjects — p=0.233
Phase 3 N=99 Center of Research Translation (CORT) Project 2
Pre-hypertension · JNC 7 Stage I Hypertension
Primary: Change in Systolic Blood Pressure (SBP) — -1.39; -1.06 mm Hg — p=0.83
Phase 2 N=253 Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels
Heart Failure · Elevated Serum Uric Acid
Primary: A Composite Clinical Endpoint (CCE) That Classifies Subject's Clinical Status as Improved, Worsened, or Unchanged. — 58; 58; 54; 43 participants
Phase 2 N=26 Lowering Serum Uric Acid to Prevent Acute Kidney Injury
Hyperuricemia
Primary: Number of Patients With Acute Kidney Injury (AKI). — 13; 13 Participants
Phase 2 N=82 A Proof-of-Concept Study of AC-201 to Prevent Gout Flares
Gout Flares
Primary: Number of Gout Flares Per Subject — 3.02; 2.45 flares — p=0.1356
N/A N=31 Effect of Reducing Uric Acid on Insulin Sensitivity and Oxidative Status
Obesity · Metabolic Syndrome · Hyperuricemia
Primary: Percent Increase in Insulin-stimulated Glucose Uptake — 231; 162; NA; 156 % incr. in insulin-mediated gluc. uptake
N/A N=80 Uric Acid and the Endothelium in CKD
Kidney Disease
Primary: Change in Endothelial Dependent Dilation From Baseline to Week 12 — 0.2; 0.9 % change — p=0.47
Phase 2 N=152 Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid
Gout Chronic · Hyperuricemia
Primary: Safety and Tolerability of Multiple Intravenous Infusions of SEL-037 or SEL-212 as Assessed by the Percentage of Participants Experiencing Serious Adverse Events and…
Phase 4 N=47 Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure
Prehypertension · Gout · Pulse Wave Velocity
Primary: Changes in 24 Hour Blood Pressure
Phase 2 N=20 Denosumab In Addition To Intense Urate-Lowering Therapy for Bone Erosions
Gout
Primary: CT Bone Erosion Score — 6.6; 7.0 Score on a scale
Phase 2 N=127 A Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Gout
Gout
Primary: Proportion of Subjects Achieving Serum Uric Acid Concentration <6.0 mg/dL — 33; 43 Participants
Phase 4 N=399 Colchicine Or Naproxen Treatment for ACute gouT
Gout
Primary: Change in Pain Intensity — 3.5; 3.8 units on a scale
Phase 4 N=1,732 Allopurinol Outcome Study
Gout
Primary: Safety of Allopurinol — 55.1 percentage of subjects
Phase 2 N=153 Dose-Response, Safety and Efficacy of Febuxostat in Subjects With Gout
Gout
Primary: Percentage of Subjects Whose Serum Urate Level Decreased to <6.0 Milligram Per Deciliter (mg/dL) at the Day 28 Visit. — 56; 76; 94; 0 percentage of subjects — p=<0.001
Phase 2 N=204 Phase II Dose Finding Study of RDEA3170 Versus Placebo in Japanese Patients With Gout or Asymptomatic Hyperuricemia
Gout and Hyperuricemia
Primary: Percent Changes of Serum Uric Acid Levels From Baseline Levels — -30.93; -49.91; -54.32; -2.05 Percent change — p=<0.0001
Phase 3 N=324 Combination Treatment Study in Subjects With Tophaceous Gout With Lesinurad and Febuxostat
Tophaceous Gout
Primary: Subjects With a Serum Urate (sUA) Level That is < 5.0 mg/dL by Month 6 — 0.566; 0.761; 0.468 Proportion of Subjects — p=0.1298
Phase 2 N=60 Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
Hyperuricemia · Albuminuria · Type 2 Diabetes
Primary: Urinary Albumin to Creatinine Ratio (UACR) — -48.65; -15.31 Precent change